Testing a new drug for advanced cancers alone and with immunotherapy
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 study tests the safety and early activity of enzelkitug, both by itself and combined with an immune therapy (a checkpoint inhibitor such as pembrolizumab or atezolizumab). It’s for people with advanced solid tumors that can’t be cured with standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You expect to live at least 12 weeks
- Your daily activity level is good (ECOG 0 or 1)
- Your cancer can be measured on scans (measurable disease)
- Your cancer type is a solid tumor that is locally advanced, recurrent, or metastatic and incurable
- You have a tumor tissue sample available for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
This Phase 1 study tests denikitug (GS-1811) alone or with zimberelimab in adults with advanced solid tumors. It’s looking mainly at safety and how the treatment works in people whose cancer has already been treated—or is not treatable with standard options.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.